Larry Gold of SomaLogic to speak at Nucleic Acid R & D Meeting, June 19&20, 2014, San Diego, CA.

CAMBRIDGE, MA, April 02, 2014 (Press-News.org) Larry Gold, Chairman of the Board at SomaLogic, to give a presentation titled "Modern Aptamers: Exciting Applications in Life Sciences, Therapeutics, and Diagnostics" at the Inaugural Nucleic Acid Research and Development Conference, June 29 & 20, 2014 in San Diego, CA.

Dr. Larry Gold is the founder and chairman of the board, and past CEO of SomaLogic. Prior to SomaLogic, he also founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc. In 1999, NeXstar merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases.

During nearly 10 years at NeXstar, Dr. Gold held numerous executive positions including chairman of the board, executive vice president of R&D, and chief science officer. Before forming NeXagen, he also co-founded and served as co-director of research at Synergen, Inc., a pioneering biotechnology company later acquired by Amgen, Inc. Since 1970, Dr. Gold has been a professor at the University of Colorado at Boulder. While at the university, he served as the chairman of the Molecular, Cellular and Developmental Biology Department from 1988 to 1992.

For more information, please visit http://www.gtcbio.com/nucleicacid/agenda

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic institutions, government organizations and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.